Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02717689
Recruitment Status : Completed
First Posted : March 24, 2016
Last Update Posted : June 25, 2020
Sponsor:
Collaborators:
Medical Research Council
Hoffmann-La Roche
Aerocrine AB
Information provided by (Responsible Party):
Liam Heaney, Belfast Health and Social Care Trust

Brief Summary:
This study explores if a composite biomarker strategy predicts exacerbation risk in patients with asthma on high dose inhaled corticosteroid (+/-long-acting beta agonist) treatment and to evaluate the utility of this composite score to facilitate personalised biomarker specific titration of corticosteroid therapy in this population.

Condition or disease Intervention/treatment Phase
Severe Persistent Asthma Other: Biomarker based adjustment of corticosteroid dose Not Applicable

Detailed Description:

Asthma affects an estimated 300 million people worldwide with a population prevalence of ca 15% in the UK. The WHO has estimated UK disability adjusted life-years per 100,000 population for asthma to be greater than diabetes and breast cancer. Much of this excessive disability is in the 10-20% of patients with asthma which is difficult to control despite currently available therapies. This high morbidity and disproportionate use of health care resources reflects the considerable unmet need in this patient group, and their significance for health care providers.

Asthma has been traditionally 'stratified' on the basis of response to 'step-wise' incremental treatment with inhaled corticosteroid (ICS) therapy forming the cornerstone of this approach. However, more recently, asthma has been stratified on the basis of inflammatory phenotype to better understand disease heterogeneity with a view to developing biomarkers of therapeutic response and for the better targeting of both new and existing treatments.

Investigators have recently examined the predictive value of a composite biomarker strategy using FeNO, blood eosinophils and serum periostin together to predict exacerbation risk in the placebo arms of clinical trials. Investigators propose to examine if this composite biomarker strategy predicts exacerbation risk in patients with asthma on high dose ICS (+/-long-acting beta agonist) treatment and to evaluate the utility of this composite score to facilitate personalised biomarker specific titration of corticosteroid therapy in this population. This study will examine subjects with FeNO<45 ppb and the scoring system will potentially allow identification of a 'low-risk' group who can safely reduce corticosteroid dose. This study will address a second important question of estimating the proportion of patients with severe disease who develop typical (T2)-driven eosinophilic inflammation on progressive corticosteroid withdrawal.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Randomised Pragmatic Trial Of Corticosteroid Optimisation In Severe Asthma Using A Composite Biomarker Algorithm To Adjust Corticosteroid Dose Versus Standard Care
Actual Study Start Date : January 1, 2016
Actual Primary Completion Date : June 19, 2019
Actual Study Completion Date : June 19, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma Steroids

Arm Intervention/treatment
Experimental: Biomarker arm
Biomarker based adjustment of corticosteroid dose.
Other: Biomarker based adjustment of corticosteroid dose
The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)

No Intervention: Standard care
The subject's corticosteroid dose will be adjusted based upon asthma symptom control and lung function



Primary Outcome Measures :
  1. Proportion of patients with any reduction in corticosteroid dose [ Time Frame: 48 weeks ]
    Proportion of patients with any reduction in oral or inhaled corticosteroid dose at any point over the 48 weeks of the study


Secondary Outcome Measures :
  1. Rate of protocol-defined severe exacerbations per patient per year [ Time Frame: 48 weeks ]
  2. Time to first severe exacerbation from randomisation [ Time Frame: 48 weeks ]
  3. Dose of inhaled steroid at end of study [ Time Frame: Week 48 ]
  4. Cumulative dose of inhaled corticosteroid during study [ Time Frame: 48 weeks ]
  5. Proportion of patients on oral corticosteroids at the end of the study [ Time Frame: Week 48 ]
  6. Proportion of patients who decline to progress to oral corticosteroids despite composite biomarker score of 2 [ Time Frame: 48 weeks ]
  7. Frequency of hospital admission for asthma [ Time Frame: 48 weeks ]
  8. Change in Asthma Control Questionnaire (ACQ-7) [ Time Frame: Week 48 ]
  9. Change in FEV1 (volume) [ Time Frame: Week 48 ]
  10. Change in exhaled breath nitric oxide level [ Time Frame: Week 48 ]
  11. Change in blood eosinophil count [ Time Frame: Week 48 ]
  12. Change in serum periostin levels [ Time Frame: Week 48 ]
  13. Change in Asthma Quality of Life Questionnaire (AQLQ) [ Time Frame: Week 48 ]

Other Outcome Measures:
  1. Exploratory biomarker analysis using whole blood gene expression [ Time Frame: 48 weeks ]
    Blood will be taken for whole blood gene expression

  2. Exploratory serum biomarker analysis [ Time Frame: 48 weeks ]
    Blood will be taken for exploratory serum biomarkers

  3. Exploratory plasma biomarker analysis [ Time Frame: 48 weeks ]
    Blood will be taken for exploratory plasma biomarkers

  4. Exploratory urinary biomarker analysis [ Time Frame: 48 weeks ]
    Urine will be taken for exploratory urine biomarkers



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 and ≤ 80 years at screening visit
  2. Able and willing to provide written informed consent and to comply with the study protocol
  3. Baseline FeNO< 45 ppb at screening
  4. Severe asthma confirmed after assessment by an asthma specialist. Diagnosed with asthma at least 12 months prior to screening
  5. Current asthma treatment with LABA plus high doses of inhaled corticosteroids (≥1000 µg FP daily or equivalent)
  6. Patients on an ICS/LABA single inhaler strategy must be switched to fixed dosing ICS/LABA for 4 weeks prior to screening
  7. Documented history of reversibility of ≥12% change in FEV1 within the past 24 months or during screening period, as demonstrated by:

    • Documented airflow obstruction (forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC ) <70%), where FEV1 has varied by ≥12% either spontaneously or in response to oral corticosteroid (OCS) therapy or bronchodilators either between or during clinic visits Or
    • A 20% drop in FEV1 (PC20) to methacholine <8 mg/mL or a 15% fall in FEV1 (PD15) after inhaling a cumulative dose of mannitol of ≤635 mg indicating the presence of airway hyperresponsiveness. If sites customarily use histamine to perform tests of airway responsiveness, this may be used in place of methacholine.

Exclusion Criteria:

  1. Acute exacerbation requiring oral corticosteroids in previous 4 weeks before screening.
  2. Known severe or clinically significant immunodeficiency, including, but not limited to, human immunodeficiency virus (HIV) infection.
  3. Currently receiving or have historically received intravenous immunoglobulin for treatment for immunodeficiency.
  4. If recently commenced on a leukotriene receptor antagonist or theophylline, stable on treatment for 4 weeks prior to screening
  5. Known current malignancy or current evaluation for a potential malignancy or history of malignancy within 5 years prior to baseline. With the exception of basal-cell and squamous-cell carcinomas of the skin and carcinoma in situ of the cervix uteri that have been excised and cured.
  6. Other clinically significant medical disease or uncontrolled concomitant disease despite treatment that is likely, in the opinion of the investigator, to require a change in therapy or impact the ability to participate in the study
  7. History of current alcohol, drug, or chemical abuse or past abuse that would impair or risk the subject's full participation in the study, in the opinion of the investigator
  8. Current self-reported history of smoking (including electronic inhaled nicotine products) or former smoker with a smoking history of >15 pack-years

    • A current smoker is defined as someone who has smoked one or more cigarettes per day (or marijuana or pipe or cigar) for ≥ 30 days within the 24 months prior to the screening visit (Day -14) and / or cotinine positive at screening
    • Any individual who smokes (cigarettes, marijuana, pipe, or cigar) occasionally, even if for < 30 days within the 24 months prior to the screening visit (Day -14), must agree to abstain from all smoking from the time of consent through completion of study
    • A former smoker is defined as someone who has smoked one or more cigarettes per day (or marijuana or pipe or cigar) for ≥ 30 days in his or her lifetime (as long as the 30-day total did not include the 24 months prior to the screening visit [Day -14]).
    • A pack-year is defined as the average number of packs per day times the number of years of smoking.
  9. Current use of an immunomodulatory/immunosuppressive therapy or past use within 3 months or five drug half-lives (whichever is longer) prior to the screening visit
  10. Use of a biologic therapy including Omalizumab at any time during the 6 months prior to the screening visit.
  11. Bronchial thermoplasty within prior 6 months of the screening visit
  12. Initiation of or change in allergen immunotherapy within 3 months prior to the screening visit.
  13. Treatment with an investigational agent within 30 days of the screening visit (or five half lives of the investigational agent, whichever is longer).
  14. Female patients who are pregnant or lactating.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02717689


Locations
Layout table for location information
United Kingdom
Belfast Health and Social Care Trust
Belfast, Northern Ireland, United Kingdom, BT9 7AB
Heart of England NHS Foundation Trust
Birmingham, United Kingdom
NHS Greater Glasgow and Clyde
Glasgow, United Kingdom
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
Royal Brompton & Harefield NHS Foundation Hospital
London, United Kingdom
University College London Hospitals NHS Foundation
London, United Kingdom
University Hospitals of South Manchester NHS Trust
Manchester, United Kingdom
Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Nottingham University Hospitals NHS Foundation Trust
Nottingham, United Kingdom
Oxford University Hospitals NHS Trust
Oxford, United Kingdom
University Hospital of Southampton NHS Foundation Trust
Southampton, United Kingdom
Sponsors and Collaborators
Belfast Health and Social Care Trust
Medical Research Council
Hoffmann-La Roche
Aerocrine AB
Investigators
Layout table for investigator information
Principal Investigator: Liam Heaney, MBBCh MRCP Queen's University, Belfast
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Liam Heaney, Professor of Respiratory Medicine, Belfast Health and Social Care Trust
ClinicalTrials.gov Identifier: NCT02717689    
Other Study ID Numbers: 001
First Posted: March 24, 2016    Key Record Dates
Last Update Posted: June 25, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases